Sanofi
Sanofi

Sanofi

DR83Ahrefs DR: 83/100. Top 25%. Measured by Ahrefs. Median 44.eDR96Effective DR: 96/100. Top 25%. Measured by StartupHub.ai. Median 68.Agent51Agent Readiness: 51/100. Top 25%. Measured by StartupHub.ai. Median 41.Speed57Site Speed: 57/100. Below median. Measured by Google PageSpeed. Median 62.

A global biopharmaceutical company focused on human health, developing and manufacturing innovative medicines and vaccines, driven by R&D and AI.

1973Active92993Paris, France

About

Sanofi is a French multinational pharmaceutical and healthcare company dedicated to improving people's lives through scientific innovation. They research, develop, manufacture, and market pharmacological products, including prescription medications, vaccines, and consumer healthcare products, with a focus on areas like immunology, neurology, oncology, and rare diseases. The company leverages AI and digital innovation in its R&D efforts.

Videos

Key facts

At-a-glance profile data

Website
sanofi.com
Headquarters
Paris, France
Founded
1973
Employees
92,993
Total funding
-
Business model
B2B

Tech stack

Detected on sanofi.com, last scanned 18 Oct 2026.

CDN
AWS CloudFront
Hosting
AWS
Email provider
Mimecast
Cookie consent
OneTrust
Hiring platform
TalentBrew
Maps
Google Maps
Integration capability
Linear
Add first review

Frequently asked

What is Sanofi's Effective Domain Rating?

StartupHub's Effective Domain Rating for Sanofi is 96 out of 100, measuring real cross-surface visibility in search engines and AI answers rather than claimed link authority. That is underrated against its Ahrefs Domain Rating of 83, meaning it surfaces in search and AI results more than its claimed authority alone would suggest.

Is Sanofi trustworthy and reputable?

StartupHub's Data Trust & Reputation score for Sanofi is 94 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.

How many employees does Sanofi have?

Sanofi has approximately 92,993 people on record.

Public companies they compete with
1
GSK
GSK

Shingrix

Sanofi's shingles prophylactic Z-1018, currently in phase 1/2 testing, could eventually challenge GSK's Shingrix.